Head-To-Head Analysis: United American Healthcare (UAHC) & T2 Biosystems (TTOO)

United American Healthcare (OTCMKTS:UAHC) and T2 Biosystems (NASDAQ:TTOO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, dividends, valuation and profitability.

Earnings & Valuation

This table compares United American Healthcare and T2 Biosystems’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
United American Healthcare N/A N/A N/A N/A N/A
T2 Biosystems $10.50 million 12.45 -$51.15 million ($1.26) -2.34

United American Healthcare has higher earnings, but lower revenue than T2 Biosystems.

Risk and Volatility

United American Healthcare has a beta of 5.65, suggesting that its share price is 465% more volatile than the S&P 500. Comparatively, T2 Biosystems has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500.

Institutional & Insider Ownership

0.2% of United American Healthcare shares are held by institutional investors. Comparatively, 49.6% of T2 Biosystems shares are held by institutional investors. 14.3% of United American Healthcare shares are held by company insiders. Comparatively, 31.5% of T2 Biosystems shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.


This table compares United American Healthcare and T2 Biosystems’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
United American Healthcare N/A N/A N/A
T2 Biosystems -487.17% -358.67% -76.77%

Analyst Ratings

This is a breakdown of current ratings and price targets for United American Healthcare and T2 Biosystems, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
United American Healthcare 0 0 0 0 N/A
T2 Biosystems 0 1 5 0 2.83

T2 Biosystems has a consensus target price of $9.25, indicating a potential upside of 213.56%. Given T2 Biosystems’ higher possible upside, analysts plainly believe T2 Biosystems is more favorable than United American Healthcare.


T2 Biosystems beats United American Healthcare on 5 of the 9 factors compared between the two stocks.

About United American Healthcare

United American Healthcare Corporation provides contract manufacturing services to the medical device industry in the United States. The company offers laser-based metal fabrication services; and supplies precision components to customers developing products for use in a range of medical specialties, including cardiology, neurology, orthopedics, gynecology, ophthalmology, and urology. Its services include precision laser cutting services for thin-wall metal tubes; laser welding services for joining metal components into sub-assemblies; CNC machining services for small custom components; and nitinol heat-treating techniques, which enable medical device developers to utilize the shape-memory properties of the nitinol material. The company also offers an array of surface treatment options to medical device manufacturers for electropolishing, passivation, and grit-blasting. Its components are used in medical device applications, such as cardiovascular stents, heart valve replacements, arterial wound closures, spinal repairs, breast biopsies, and brain aneurysm repairs. United American Healthcare Corporation was founded in 1983 and is based in Chicago, Illinois.

About T2 Biosystems

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company also offers T2Dx, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood. In addition, it is developing Candida Auris, a multi-drug resistant pathogen; T2Bacteria, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; and T2Lyme for the detection of various strains of Lyme disease-causing bacteria. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease; and Allergan Sales, LLC to develop detection diagnostic test panel that adds one additional bacteria species to the existing T2Bacteria product candidate, as well as for testing drug resistance directly in whole blood. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.

Receive News & Ratings for United American Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United American Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit